Redhill Biopharma Ltd (RDHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has a cash flow conversion efficiency ratio of 0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($-4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RDHL days of operational coverage to measure how many days the company can operate on defensive assets alone.
Redhill Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Redhill Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redhill Biopharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BGT Corporation Public Company Limited
BK:BGT
|
0.217x |
|
Riedel Resources Ltd
AU:RIE
|
-0.041x |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
-0.087x |
|
Matinas BioPharma Holdings Inc
NYSE MKT:MTNB
|
-0.530x |
|
Falmaco Nonwoven Industri PT Tbk
JK:FLMC
|
-0.007x |
|
Aquaporin AS
CO:AQP
|
-0.157x |
|
Whitehawk Ltd
AU:WHK
|
-1.847x |
|
Spartoo SAS
PA:ALSPT
|
0.090x |
Annual Cash Flow Conversion Efficiency for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see RDHL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.27 Million | $-9.65 Million | -2.261x | -213.03% |
| 2024-12-31 | $-4.68 Million | $-9.37 Million | 2.001x | +111.56% |
| 2023-12-31 | $2.07 Million | $-35.82 Million | -17.313x | -2971.10% |
| 2022-12-31 | $-48.40 Million | $-29.18 Million | 0.603x | +108.23% |
| 2021-12-31 | $8.88 Million | $-65.05 Million | -7.329x | -109.17% |
| 2020-12-31 | $13.86 Million | $-48.58 Million | -3.504x | -415.95% |
| 2019-12-31 | $60.00 Million | $-40.75 Million | -0.679x | -0.87% |
| 2018-12-31 | $51.19 Million | $-34.46 Million | -0.673x | +32.23% |
| 2017-12-31 | $45.06 Million | $-44.77 Million | -0.993x | -120.43% |
| 2016-12-31 | $62.70 Million | $-28.26 Million | -0.451x | -51.89% |
| 2015-12-31 | $60.08 Million | $-17.83 Million | -0.297x | +39.31% |
| 2014-12-31 | $25.01 Million | $-12.23 Million | -0.489x | +30.88% |
| 2013-12-31 | $11.93 Million | $-8.44 Million | -0.707x | -97.99% |
| 2012-12-31 | $19.02 Million | $-6.79 Million | -0.357x | -43.09% |
| 2011-12-31 | $18.79 Million | $-4.69 Million | -0.250x | -124.39% |
| 2010-12-31 | $-1.59 Million | $-1.63 Million | 1.024x | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more